Decoy Therapeutics (FP11) Stock Price & Analysis
FP11 Stock Chart & Stats
- Day’s Range
- EUR 5.23 - EUR 7.20
- 52-Week Range
- EUR 4.20 - EUR 38.64
- Previous Close
- EUR 5.23
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 2.29M
- Enterprise Value
- -EUR 4.66T
- Total Cash (Recent Filing)
- EUR 8.29M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 1.09
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
The absence of debt reduces mandatory interest and principal obligations, giving Decoy greater flexibility while it funds research and development. This lowers balance-sheet solvency pressure and leaves fewer creditor claims competing with operating cash, although it does not eliminate the need for future financing.
Near-term Liquidity Injection
The approximately $3.85 million proceeds provide additional working capital for a pre-revenue company with ongoing cash needs. That liquidity can extend operational capacity and support development activities over the next several months, even though the related warrant issuance creates future dilution exposure.
Historical Loss Improvement
The reduction in annual losses from 2022 through 2024 shows that Decoy has previously demonstrated some ability to moderate its spending burden. If that improvement can be regained, lower losses could extend cash runway and improve the path toward sustainable economics, despite recent deterioration.
Bears Say
Pre-revenue Business Model
With no recorded revenue, Decoy currently lacks an operating income stream to fund research, corporate costs, or future expansion. The company therefore depends on financing and successful development or commercialization of candidates before it can establish recurring revenue and operating leverage.
Persistent Cash Burn
Negative operating and free cash flow indicate that core activities continue to consume cash rather than generate internally funded growth. Sustained burn reduces financial flexibility, increases dependence on external capital, and can force management to prioritize fundraising over longer-term development execution.
Shrinking Equity And Dilution Risk
The steep decline in equity indicates that historical losses have consumed a substantial portion of the capital base. Additional warrant-linked shares may provide funding, but they can dilute existing holders and signal that future operating needs may continue to require equity-based financing.
Decoy Therapeutics News
FP11 FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
What is Decoy Therapeutics’s market cap?
When is Decoy Therapeutics’s upcoming earnings report date?
How were Decoy Therapeutics’s earnings last quarter?
Is Decoy Therapeutics overvalued?
Does Decoy Therapeutics pay dividends?
What is Decoy Therapeutics’s EPS estimate?
How many shares outstanding does Decoy Therapeutics have?
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Decoy Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Frederick E. Pierce
- Employees
- 11
- Website
- decoytx.com
- Address
- 2450 Holcombe Blvd, Houston, TX, 77021, US
Decoy Therapeutics (FP11) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 1 | 10 |
| Technical Analysis | 4 | 1 | 2 |
| Moving Averages | 4 | 0 | 8 |
